The Ultragenyx Pharmaceutical Inc (RARE) share price is expected to increase by 82.85% over the next year. This is based on calculating the average 12-month share price estimate provided by 11 stock analysts who have covered RARE. Price targets range from $48.00 at the low end to $130.00 at the high end. The current analyst consensus for RARE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Ultragenyx Pharmaceutical Inc has a total of 11 Wall St Analyst ratings. There are 10 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Ultragenyx Pharmaceutical Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
laura chico Wedbush | Hold | $48.0 | maintained | Feb 16, 2024 |
gena wang Barclays | Buy | $81.0 | reiterated | Feb 15, 2024 |
ed arce H.C. Wainwright | Buy | $82.0 | maintained | Feb 7, 2024 |
whitney ijem Canaccord Genuity | Buy | $110.0 | maintained | Feb 7, 2024 |
joseph schwartz Leerink Partners | Buy | None | reiterated | Feb 6, 2024 |
jack allen Robert W. Baird | Buy | $68.0 | maintained | Jan 30, 2024 |
yaron werber TD Cowen | Buy | $59.0 | maintained | Jan 25, 2024 |
anupam rama J.P. Morgan | Buy | $84.0 | maintained | Jan 17, 2024 |
dae gon ha Stifel Nicolaus | Buy | $124.0 | maintained | Jan 15, 2024 |
christopher raymond Piper Sandler | Buy | $130.0 | rated | Jan 8, 2024 |
yigal nochomovitz Citi | Buy | $126.0 | maintained | Jan 7, 2024 |
tiago fauth Wells Fargo | Buy | $72.0 | initiatedcoverage | Dec 7, 2023 |
joon lee Truist Financial | Buy | $140.0 | maintained | Nov 10, 2023 |
jeffrey hung Morgan Stanley | Buy | $84.0 | maintained | Nov 3, 2023 |
joel beatty Robert W. Baird | Buy | $57.0 | maintained | Nov 2, 2023 |
tazeen ahmad Bank of America Securities | Buy | $84.0 | maintained | Oct 16, 2023 |
salveen richter Goldman Sachs | Hold | $52.0 | maintained | Aug 4, 2023 |
kristen kluska Cantor Fitzgerald | Buy | $114.0 | reiterated | Aug 3, 2023 |
mark purcell Morgan Stanley | Buy | $95.0 | maintained | Jun 22, 2023 |
liisa bayko Evercore ISI | Buy | $80.0 | upgraded | Jun 6, 2023 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
When did it IPO
2014
Staff Count
1,311
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Market Cap
$4.02B
In 2023, RARE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RARE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
FOLD-USD
$13.56
IPGP-USD
$86.28
ACAD-USD
$24.85
LNTH-USD
$57.46
MRTX-USD
$58.7
PGNY-USD
$40.78